<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The safety and efficacy of rituximab with CODOX-M/IVAC (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, <z:chebi fb="0" ids="44185">methotrexate</z:chebi>/ifosfamide, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, high dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi>) was retrospectively analysed in 23 patients with non-human <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> virus-related B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> with proliferation index &gt;95% [14 with classical Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), five with B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> unclassifiable, with features intermediate between diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, and four with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>] </plain></SENT>
<SENT sid="1" pm="."><plain>Six (26%) low-risk (LR) patients received three cycles of CODOX-M and 17 (74%) high-risk (HR) cases were assigned to four cycles of alternating CODOX-M/IVAC </plain></SENT>
<SENT sid="2" pm="."><plain>Rituximab 375 mg/mÂ² was infused on days 1 and 10 of each cycle </plain></SENT>
<SENT sid="3" pm="."><plain>Toxicity was comparable to that reported with CODOX-M/IVAC, with no treatment-related <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients developed grade 3 rituximab-induced delayed <z:hpo ids='HP_0001875'>neutropenia</z:hpo>, with no adverse outcome </plain></SENT>
<SENT sid="5" pm="."><plain>After completing treatment, 83% LR patients and 71% HR patients achieved CR by <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography-computerized tomography (PET-CT) </plain></SENT>
<SENT sid="6" pm="."><plain>Three (13%) patients received salvage treatment </plain></SENT>
<SENT sid="7" pm="."><plain>At a median follow-up of 34 months (range = 18-75), 19 (83%) patients (100% LR and 74% HR) were alive, including one case undergoing salvage for late relapse </plain></SENT>
<SENT sid="8" pm="."><plain>Four HR patients (17%) had died, three from primary progressive disease and one from treatment-refractory relapse 2 months after achieving CR </plain></SENT>
<SENT sid="9" pm="."><plain>These results with R-CODOX-M/R-IVAC compare favourably with existing data using CODOX-M/IVAC and warrant further prospective studies </plain></SENT>
<SENT sid="10" pm="."><plain>The potential pitfalls of PET-CT to assess response are highlighted </plain></SENT>
</text></document>